Biotechs: An Expert Opinion Bio-tech stalwart Amgen (Nasdaq:AMGN) crushed earnings estimates Monday afternoon (July 28) and raised guidance to boot. The stock was up 4% on Tuesday. Most biotech ETFs were up 1% or so in response. That lends a little credence...